Hangzhou Tigermed Consulting Co., Ltd (HNGZY)

OTCMKTS · Delayed Price · Currency is USD
4.000
0.00 (0.00%)
Mar 26, 2026, 4:00 PM EST
Market Cap6.31B +1.2%
Revenue (ttm)921.64M -3.5%
Net Income85.99M -36.1%
EPS0.10 -35.6%
Shares Outn/a
PE Ratio73.40
Forward PE36.21
Dividend0.03 (0.72%)
Ex-Dividend DateJun 13, 2025
Volumen/a
Average Volume454
Open4.000
Previous Close4.000
Day's Range4.000 - 4.000
52-Week Range4.000 - 4.300
Beta0.68
RSIn/a
Earnings DateMar 30, 2026

About HNGZY

Hangzhou Tigermed Consulting Co., Ltd, together with its subsidiaries, provides contract research organization services in the People’s Republic of China and internationally. It operates through Clinical Trial Solutions; and Clinical-related and Laboratory Services segments. The company offers preclinical development services, including medicinal chemistry, compound screening, DMPK, safety and toxicology, bioanalytical, and formulation research and development services; and clinical development services, such as medical writing, clinical monito... [Read more]

Sector Healthcare
Founded 2004
Employees 10,185
Stock Exchange OTCMKTS
Ticker Symbol HNGZY

Financial Performance

In 2024, HNGZY's revenue was 6.60 billion, a decrease of -10.58% compared to the previous year's 7.38 billion. Earnings were 405.14 million, a decrease of -79.99%.

Financial numbers in CNY Financial Statements